Argent Biopharma Limited has released a press release.
$800,000 of funding received through Mercer Facility
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- Completion of CimetrA Efficacy Pre-clinical Trial
- US$1,000,000 ArtemiC order delivered to US partner, AMC
- Publication of Peer Reviewed Glioblastoma Research
- Long COVID study Results
- Pause in Trading
Later from Argent Biopharma
- Internal Costs Review Completed and Board Change
- Results of CimetrA bioanalytics pre-clinal trial
- Refinancing and Extension to Convertible Security Agreements
- Provision of US$600,000 Funding and change of CFO
- Completion of CimetrA Mechanism of Action study
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma